Screening for differences in the amorphous state of indomethacin using multivariate visualization

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 2, 2007, Pages 113-123

  Savolainen, Marja ^a   Heinz, Andrea ^b   Strachan, Clare ^a   Gordon, Keith C ^b   Yliruusi, Jouko ^a   Rades, Thomas ^b   Sandler, Niklas ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Amorphous state; Indomethacin; Principal component analysis; Spectroscopic techniques

Indexed keywords

ALPHA INDOMETACIN; GAMMA INDOMETACIN; INDOMETACIN; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SCREENING; GENETIC POLYMORPHISM; HUMAN; HYDROGEN BOND; MELTING POINT; MOLECULAR MECHANICS; MULTIVARIATE ANALYSIS; NEAR INFRARED SPECTROSCOPY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SPRAY DRYING; X RAY POWDER DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DIFFERENTIAL THERMAL ANALYSIS; DRUG STABILITY; INDOMETHACIN; MOLECULAR STRUCTURE; PRINCIPAL COMPONENT ANALYSIS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTROSCOPY, NEAR-INFRARED; SPECTRUM ANALYSIS, RAMAN;

EID: 33846425782     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.10.010     Document Type: Article

References (27)

1. Andronis V., and Zografi G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J. Non-Cryst. Solids 271 (2000) 236-248
2. Andronis V., Yoshioka M., and Zografi G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J. Pharm. Sci. 86 3 (1997) 346-351
3. Billinger S.J., and Kanatzidis M.G. Beyond crystallography: the study of disorder, nanocrystallinity and crystallographically challenged materials with pair distribution functions. Chem. Commun. (2004) 749-760
4. Chen X., Morris K.R., Griesser U.J., Byrn S.R., and Stowell J.G. Reactivity differences of indomethacin solid forms with ammonia gas. J. Am. Chem. Soc. 124 (2002) 15012-15019
5. Colthup N.B., Daly L.H., and Wiberley S.E. Introduction to Infrared and Raman Spectroscopy. 3rd ed. (1990), Academic Press, San Diego, CA, USA
6. Cox P.J., and Manson P.L. γ-Indomethacin at 120 K. Acta Cryst. E 59 (2003) 986-988
7. Grant D.J.W. Theory and origin of polymorphism. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids vol. 95 (1999), Marcel Dekker, New York 1-33
8. Hancock B.C., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 1 (1997) 1-12
9. Hancock B.C., Shalaev E.Y., and Shamblin S.L. Polyamorphism: a pharmaceutical science perspective. J. Pharm. Pharmacol. 54 (2002) 1151-1152
10. Hess S., Teubert U., Ortwein J., and Eger K. Profiling indomethacin impurities using high-performance liquid chromatography and nuclear magnetic resonance. Eur. J. Pharm. Sci. 14 (2001) 301-311
11. Juhás P., Cherba D.M., Duxbury P.M., Punch W.F., and Billinge S.J.L. Ab initio determination of solid-state nanostructure. Nature 440 (2006) 655-658
12. Lin-Vien D., Colthup N.B., Fateley W.G., and Graselli J.G. The Handbook of Infrared and Raman Characteristic Frequencies of Organic Molecules (1991), Academic Press, San Diego, CA, USA
13. Ohta M., and Buckton G. A study of differences between two amorphous spray-dried samples of cefditoren pivoxil which exhibited different physical stabilities. Int. J. Pharm. 289 (2005) 31-38
14. Otsuka M., and Kaneniwa N. A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem. Pharm. Bull. 36 10 (1988) 4026-4032
15. Otsuka M., Kato F., and Matsuda Y. Comparative evaluation of the degree of indomethacin crystallinity by chemoinfometrical Fourier-transformed near-infrared spectroscopy and conventional powder X-ray diffractometry. AAPS Pharmsci. 2 1 (2000) (Article 9)
16. Otsuka M., Kato F., and Matsuda Y. Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry. Analyst 126 (2001) 1578-1582
17. Patterson J.E., James M.B., Forster A.H., Lancaster R.W., Butler J.M., and Rades T. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J. Pharm. Sci. 94 9 (2005) 1998-2012
18. Pikal M.J. Impact of polymorphism on the quality of lyophilized products. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids vol. 95 (1999), Marcel Dekker, New York 1-33
19. Rodríguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., and Rodríguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Deliv. Rev. 56 (2004) 241-274
20. Savolainen, M., Jouppila, K., Pajamo, O., Christiansen, L., Strachan, C., Karjalainen, M., Rantanen, J., in press. Determination of amorphous content in the pharmaceutical process environment. J. Pharm. Pharmacol.
21. Sheth A.R., Bates S., Muller F.X., and Grant D.J.W. Polymorphism of piroxicam. Cryst. Growth Des. 4 6 (2004) 1092-1098
22. Sheth A.R., Bates S., Muller F.X., and Grant D.J.W. Local structure in amorphous phases of piroxicam from powder X-ray diffractometry. Cryst. Growth Des. 5 2 (2005) 571-578
23. Siesler H.W., Ozaki Y., Kawata S., and Heise H.M. Near-Infrared Spectroscopy: Principles, Instruments, Applications (2002), Wiley-VCH Verlag GmbH, Weinheim, Germany pp. 335-338
24. Strachan, C.J., Rades, T., Gordon K.C., in press. A theoretical and spectroscopic study of γ-crystalline and amorphous indomethacin. J. Pharm. Pharmacol.
25. Taylor L.S., and Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14 12 (1997) 1691-1698
26. Yoshioka M., Hancock B.C., and Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83 12 (1994) 1700-1705
27. Zhang G.G.Z., Law D., Schmitt E.A., and Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug Deliv. Rev. 56 (2004) 371-390